4F2hc/SLC3A2 (D5U4G) XP® Rabbit mAb #94274
- WB
- IHC
- IF
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 75-120 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunohistochemistry (Paraffin) | 1:300 |
| Immunofluorescence (Immunocytochemistry) | 1:100 |
Storage
Protocol
Specificity / Sensitivity
4F2hc/SLC3A2 (D5U4G) XP® Rabbit mAb recognizes endogenous levels of total 4F2hc/SLC3A2 protein. This antibody is predicted to detect multiple isoforms of 4F2hc/SLC3A2.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala629 of human 4F2hc/SLC3A2 protein.
Background
4F2hc is a transmembrane protein that belongs to the solute carrier family. 4F2hc forms heterodimeric complexes with various amino acid transporters such as LAT1 and LAT2 and regulates uptake of amino acids (1-5). 4F2hc is one of the earliest expressed antigens on the surface of activated human lymphocytes (6), hence it is also named CD98. 4F2hc is expressed in all cell types with the exception of platelets, and is expressed at highest levels in the tubules of the kidney and the gastrointestinal tract (7,8). It is localized at the plasma membrane when associated with LAT1 or LAT2 (9) and at the apical membrane of placenta (10). Research studies have shown that 4F2hc is highly expressed in various tumors including glioma (11), ovarian cancer (12), and astrocytomas (13), and it has been implicated in tumor progression and correlated with poor outcome in patients with pulmonary neuroendocrine tumors (14). 4F2hc is also involved in integrin trafficking through association with β1 and β4 integrins, and regulates keratinocyte adhesion and differentiation (15).
- Kanai, Y. et al. (1998) J Biol Chem 273, 23629-32.
- Mastroberardino, L. et al. (1998) Nature 395, 288-91.
- Pfeiffer, R. et al. (1999) EMBO J 18, 49-57.
- Pineda, M. et al. (1999) J Biol Chem 274, 19738-44.
- Sato, H. et al. (1999) J Biol Chem 274, 11455-8.
- Lumadue, J.A. et al. (1987) Proc Natl Acad Sci USA 84, 9204-8.
- Rossier, G. et al. (1999) J Biol Chem 274, 34948-54.
- Dave, M.H. et al. (2004) J Physiol 558, 597-610.
- Bröer, A. et al. (2001) Biochem J 355, 725-31.
- Ritchie, J.W. and Taylor, P.M. (2001) Biochem J 356, 719-25.
- Okubo, S. et al. (2010) J Neurooncol 99, 217-25.
- Kaji, M. et al. (2010) Int J Gynecol Cancer 20, 329-36.
- Nawashiro, H. et al. (2006) Int J Cancer 119, 484-92.
- Kaira, K. et al. (2011) Oncol Rep 26, 931-7.
- Lemaître, G. et al. (2011) J Dermatol Sci 61, 169-79.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.